Participated in DiogenX's EUR 27.5M Series A financing for diabetes biologics.
MAY 2023
DiogenX is a preclinical stage biotech company committed to a single mission: to discover and develop innovative biologics as new therapeutics options for millions of diabetic patients around the world
DiogenX is a preclinical stage biotech company committed to a single mission: to discover and develop innovative biologics as new therapeutics options for millions of diabetic patients around the world. The company is focused on developing a first-in-class regenerative treatment for type 1 diabetes, specifically through its lead program DGX-01, which modulates the Wnt/β-catenin signaling pathway to regenerate insulin-producing pancreatic beta cells.